

August 11, 2006

Ms. Rachel Browder  
U.S. Nuclear Regulatory Commission  
Region IV: DNMS: NMLB  
Suite 400  
611 Ryan Plaza Drive  
Arlington, TX 76011

**SUBJECT: ANALYTICAL RESULTS FOR FIVE SMEAR SAMPLES  
COLLECTED AUGUST 3, 2006 FROM GLAXOSMITHKLINE  
BIOLOGICALS IN HAMILTON, MONTANA  
(INSPECTION REPORT #030-19324/2006-001) [RFTA NO. 06-001]**

Dear Ms. Browder:

The Oak Ridge Institute for Science and Education (ORISE) received five smear samples for analysis from GlaxoSmithKline Biologicals in Hamilton, Montana on August 4, 2006. The smear samples were analyzed for tritium (H-3) (AP2, Revision 15) and carbon-14 (C-14) (AP9, Revision 3) by liquid scintillation analysis (CP4, Revision 3). The H-3 and C-14 measured activities were below the minimum detectable concentrations (MDC) for each analysis. The H-3 MDC was 16.7 pCi/smear and the C-14 concentration was 5.8 pCi/smear.

ORISE's Quality Control (QC) requirements were met for these analyses. The QC files are available for your review upon request.

My contact information is listed below. You may also contact Wade Ivey at 865.576.9184 with any questions or comments.

Sincerely,



Dale Condra, Manager  
Laboratory

RDC/WPI: ar

c: B. Watson, NMSS/DWMEP/DD/SP 7E18  
E. Knox-Davin, NRC/NMSS/TWFN T8A23  
File 1716

E. Abelquist, ORISE  
S. Kirk, ORISE

Distribution approval and concurrence:	Initials
Technical Management Team Member	<i>[Signature]</i> SSK
Quality Manager	MAB for Ann Payne

Voice: 865.241.3242

Fax: 865.241.3248

E-mail: CondraD@ornl.gov